Home › Endometrial Cancer › Oregon › Portland
Endometrial Cancer clinical trials in Portland, OR
24 studies for Endometrial Cancer are looking for participants at sites in and around Portland (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RecruitingPhase 2
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RecruitingPhase 1/2
- Oregon Health & Science University (OHSU), Portland
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
RecruitingPhase 3
- Legacy Good Samaritan Hospital and Medical Center, Portland
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
RecruitingPhase 1
- Site 02, Portland
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
RecruitingPhase 2
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
Study of AVZO-021 in Patients With Advanced Solid Tumors
RecruitingPhase 1/2
- Avenzo Therapeutics Recruiting Site, Portland
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
RecruitingPhase 1
- Research Site, Portland
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
RecruitingPhase 2
- Providence Portland Medical Centre, Portland
- Providence Saint Vincent Medical Center, Portland
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RecruitingPhase 1
- Providence Portland Medical Center, Portland
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
RecruitingPhase 3
- USOR - NW Cancer Specs P.C., Portland
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
RecruitingPhase 1
- Providence Cancer Institute of Oregon, Portland
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RecruitingPhase 1/2
- Research Site, Portland
FOG-001 in Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 1/2
- Oregon Health and Science University, Portland
A Study of MGC026 in Participants With Advanced Solid Tumors
RecruitingPhase 1
- Providence Cancer Institute, Portland
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RecruitingPhase 1/2
- Compass Oncology - Rose Quarter, Portland
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RecruitingPhase 1/2
- Oregon Health & Science University, Portland
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
RecruitingPhase 3
- Research Site, Portland
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
RecruitingPhase 1
- Investigative Site #121, Portland
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
RecruitingPhase 1/2
- Providence Cancer Institute Franz Clinic, Portland
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
RecruitingObservational studyHealthy volunteers welcome
- Oregon Health Sciences University, Portland
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
RecruitingPhase 2
- Northwest Cancer Specialists, P.C., Portland
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Portland
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
RecruitingPhase 1/2
- Oregon Health & Science University, Portland
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
RecruitingPhase 2/3
- Northwest Cancer Specialists, Portland
Endometrial Cancer trials in other cities
- Houston, TX68 studies
- New York City, NY52 studies
- Boston, MA50 studies
- Arlington, VA39 studies
- Nashville, TN38 studies
- Los Angeles, CA34 studies
- St. Louis, MO29 studies
- Philadelphia, PA28 studies
- San Antonio, TX27 studies
- Chicago, IL25 studies
- Columbus, OH25 studies
- Queens, NY25 studies
Other studies in Portland
- Non-Small Cell Lung Cancer46 studies
- Cancer (all types)34 studies
- Prostate Cancer33 studies
- Breast Cancer33 studies
- Metastatic Cancer29 studies
- Colorectal Cancer28 studies
- Ovarian Cancer27 studies
- Lung Cancer26 studies
- Acute Myeloid Leukemia25 studies
- Head and Neck Squamous Cell Carcinoma19 studies
- Pancreatic Cancer19 studies
- Heart Failure17 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.